Rubicon Research Limited buys 85% of Arinna for Rs 175.92 crore

Rubicon Research Limited acquired an 85% equity stake in Arinna Lifesciences Limited for Rs 175.92 crore on April 30, 2026, and a wholly owned subsidiary also acquired a New Jersey manufacturing facility at a USD 2.9 million enterprise value during the September 2026 quarter. The Arinna transaction was accounted for using provisional business-combination values.

What did Rubicon Research pay for its Arinna stake?

Rubicon Research paid Rs 175.92 crore for 85% of Arinna Lifesciences on April 30, 2026. The group accounted for the transaction under Indian Accounting Standard 103, Business Combinations, using provisional fair values for identifiable assets acquired and liabilities assumed.

The half-year cash-flow statement records Rs 175.92 crore as consideration paid for acquiring a subsidiary through a business combination. It also records Rs 8.33 crore of cash and cash equivalents acquired in that business combination, while net cash used in investing activities was Rs 171.91 crore for the half year ended September 30, 2026.

The filing says Arinna's results are included from the acquisition date and cautions that the corresponding earlier periods are therefore not directly comparable. Rubicon Research reports a single operating segment, sale of pharmaceutical products, and does not disclose separate revenue, profit or asset figures for Arinna.

How did Arinna change Rubicon Research's balance sheet?

Rubicon Research's total assets increased by Rs 434.10 crore to Rs 2,760.81 crore at September 30, 2026, from Rs 2,326.71 crore at March 31, 2026. Non-current assets rose by Rs 368.70 crore to Rs 1,013.60 crore, while current assets increased by Rs 65.40 crore to Rs 1,747.21 crore.

Goodwill rose by Rs 95.56 crore to Rs 149.47 crore, and intangible assets increased by Rs 115.52 crore to Rs 126.23 crore over the six months. The filing does not attribute those movements solely to Arinna, but confirms that the stake acquisition used provisional fair values under the business-combination standard.

Non-controlling interests, which represent equity interests held by owners outside the group, increased to Rs 14.74 crore at September 30 from Rs 0.001 crore at March 31. Rubicon Research owns 85%, rather than all, of Arinna; however, the filing does not explicitly allocate the non-controlling-interest balance to a particular subsidiary.

What US manufacturing facility did Rubicon Research acquire?

Rubicon Research added a manufacturing facility in East Brunswick, New Jersey, through AdvaGen Holdings Inc., its wholly owned subsidiary. AdvaGen Holdings acquired the facility from InvaTech Pharma Solutions, LLC during the quarter ended September 30, 2026, at an enterprise value of USD 2.9 million.

The announcement does not disclose the facility's production capacity, product categories, staffing, regulatory status, consideration in rupees or commercial start date. It also does not state whether the deal was structured as an asset purchase or another form of transaction.

The facility acquisition followed the April 30 Arinna transaction in the same half year that Rubicon Research reported Rs 94.94 crore of capital expenditure. The filing does not separate the New Jersey facility's spending from other capital expenditure, although capital work in progress rose to Rs 90.15 crore at September 30 from Rs 40.46 crore at March 31.

How did Rubicon Research's cash generation and earnings change?

Rubicon Research generated Rs 98.86 crore of net operating cash flow in the half year ended September 30, 2026, compared with Rs 104.48 crore a year earlier. Cash generated from operations before income tax increased to Rs 152.11 crore from Rs 116.84 crore, but income tax paid rose to Rs 53.25 crore from Rs 12.35 crore.

Working capital absorbed cash as inventories increased by Rs 57.88 crore and trade receivables increased by Rs 80.96 crore in the six-month period. Trade payables fell by Rs 14.26 crore, while provisions increased by Rs 50.57 crore.

Consolidated revenue from operations increased to Rs 1,110.72 crore in the half year from Rs 764.51 crore a year earlier. Profit before tax rose to Rs 227.29 crore from Rs 131.26 crore and profit after tax increased to Rs 175.21 crore from Rs 97.15 crore, although the Arinna consolidation means these periods are not directly comparable.

What funding remains available for Rubicon Research's plans?

Rubicon Research had Rs 64.60 crore of unutilised net initial public offering, or IPO, proceeds at September 30, 2026. Of Rs 471.27 crore in net proceeds, Rs 406.68 crore had been used, including Rs 291.41 crore for repayment or prepayment of certain borrowings and Rs 115.27 crore for inorganic growth, strategic initiatives and general corporate purposes.

The board approved an extension of the deadline to use the unutilised IPO proceeds until March 31, 2027, on May 29, 2026. Within the inorganic-growth, strategic-initiatives and corporate-purpose allocation, Rs 46.01 crore remained unused at September 30, but the filing identifies no further acquisition target.

Rubicon Research reported total borrowings of Rs 398.37 crore at September 30, comprising Rs 188.48 crore of non-current borrowings and Rs 209.90 crore of current borrowings. During the half year, current borrowings generated net proceeds of Rs 90.61 crore, while non-current borrowings generated net proceeds of Rs 40.43 crore after proceeds and repayments.

Conclusion

Rubicon Research completed two disclosed expansion transactions during the half year ended September 30, 2026: the Rs 175.92 crore purchase of an 85% stake in Arinna and the USD 2.9 million enterprise-value acquisition of a New Jersey manufacturing facility. The period also brought increases in assets, goodwill, intangible assets and non-controlling interests, alongside Rs 171.91 crore of net investing cash outflow.

The next disclosed date to watch is March 31, 2027, the extended deadline for using Rs 64.60 crore of unutilised IPO proceeds. Rubicon Research may also provide further accounting detail when the provisional fair values used for the Arinna business combination are finalised, while the filing leaves the operating role of the East Brunswick facility unresolved.